Skip to main content
Premium Trial:

Request an Annual Quote

Biocept Prices $2.2M Registered Direct Offering

NEW YORK (GenomeWeb) – Biocept said today that it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately 990,000 shares of its common stock at a price of $2.25 per share, resulting in gross proceeds of approximately $2.2 million.

Maxim Group is acting as the lead placement agent and Dawson James Securities is co-placement agent for the offering, which is expected to close on or about January 23, subject to the satisfaction of customary closing conditions.

The shares of common stock are being offered pursuant to a shelf registration statement, declared effective by the US Securities and Exchange Commission on May 24, 2018.

The direct offering comes about a month after Biocept said in a regulatory filing that it was reducing to $5.4 million the expected proceeds from a public offering it had previously said would bring in $9.1 million.

In early morning trading on the Nasdaq, Biocept's shares were down about 15 percent at $2.59.

The Scan

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.

Active Lifestyle Linked to Type 2 Diabetes Prevention in People at High Genetic Risk

A study in the British Journal of Sports Medicine shows that an active lifestyle goes a long way in type 2 diabetes prevention.

Beneficial, Harmful Effects of Introgression Between Wild and Domesticated European Grapes

A paper in PNAS shows that European wild grapevines were an important resource for improving the flavor of cultivated wine grapes.

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.